Click to View in Browser
Monday, December 25, 2017
Concussion protocol altered after recent missteps
(Reuters) - The NFL's concussion protocol has been altered with late-season changes following recent incidents that have triggered investigations.
Israel's Super-Pharm in talks to buy Teva Pharm plant: source
TEL AVIV (Reuters) - Israel's largest pharmacy chain Super-Pharm (Israel) Ltd is in talks to acquire Teva Pharmaceutical Industries' plant in the coastal city of Ashdod, a source familiar with the matter said on Sunday, confirming media reports.
Boston-area paramedics on front lines of U.S. opioid crisis
(Reuters) - The paramedics find them everywhere - slumped over car steering wheels, barely breathing in doughnut shop bathrooms or dead in derelict apartments and expensive mansions.
FDA rejects Agile's contraceptive patch, shares plunge
(Reuters) - Agile Therapeutics Inc said on Friday the U.S. Food and Drug Administration declined to approve its contraceptive patch for the second time, sending the drug developer's shares down about 50 percent.
U.S. judge tosses verdict against AbbVie in AndroGel case
(Reuters) - A U.S. judge on Friday overturned a $150 million verdict against AbbVie Inc that was the first to result from lawsuits claiming that the company fraudulently misrepresented the risks of its testosterone replacement drug AndroGel.
Kmart to pay $32 million to settle drug overbilling allegations
WASHINGTON (Reuters) - Kmart Corp, a unit of Sears Holdings Corp, has agreed to pay $32.3 million to settle allegations that its pharmacies failed to report discounted prescription drug prices to federal health programs, the U.S. Justice Department said on Friday.
Ocular Therapeutix gets subpoena from SEC over eye pain drug
(Reuters) - Ocular Therapeutix Inc said on Friday the U.S. Securities and Exchange Commission (SEC) had issued a subpoena seeking information about the company's eye-pain drug Dextenza.
Valeant says Bausch & Lomb's over-the-counter eye drop gets FDA nod
(Reuters) - Canadian drugmaker Valeant Pharmaceuticals International Inc said the U.S. Food and Drug Administration approved Lumify drop to treat eye redness.
Common blood pressure drug tied to increased risk of skin cancer
(Reuters Health) - People who take a certain water pill prescribed to control fluid retention and treat high blood pressure may be more likely to get skin cancer than other individuals, a Danish study suggests.
U.S. FDA plans to let device makers report malfunctions less frequently
(Reuters) - The U.S. Food and Drug Administration on Friday said it plans to let medical device makers report less serious malfunctions of some devices on a quarterly basis to cut down on repeated reviews of common problems.
Related Video
MIT researchers invent device to save water-stressed plants
Heavy rain triggers floodings in Northern Italy
A quick-fix on the day's news delivered when you want it. Register Today
A daily digest of breaking business news, coverage of the US economy, major corporate news and the financial markets. Register Today
» » MORE NEWSLETTERS
- 3 Times Square New York, NY 10036 USA © Copyright 2017 Thomson Reuters
Ensure delivery of Reuters Newsmails, add newsletters@email.reuters.com to your address book.
Subscribe to other Reuters newsletters.
Unsubscribe from this newsletter.
Follow us on Twitter Friend us on Facebook